Member Info for Laura2022

Monte Muambe #fluorspar #gallium resource definition samples have arrived safely at the lab in South Africa. Sample prep has started.

Key Market Segments & Sizes (Estimates):

Biostatistics Consulting Services: Valued around $6.5 billion (2024) and expected to reach $10-20+ billion by 2033, with CAGRs often cited between 6.5% to over 12%.

Biostatistics Software: Valued at $5.73 billion in 2025, projected to grow to $14.61 billion by 2033 (CAGR ~16.88%).

Biostatistics Certification: Valued at $1.6 billion in 2025, forecast to reach $3.2 billion by 2033.

Growth Drivers:

Increased R&D: Surge in pharmaceutical and medical device research, particularly in cancer and chronic diseases.

Clinical Trials: Growing complexity and number of clinical trials requiring robust statistical analysis.

Technology: Adoption of AI, machine learning, and advanced analytics in healthcare and life sciences.

Global Demand: Expansion into emerging markets like Asia-Pacific.

Market Dynamics:

The market is characterized by strong demand from pharmaceutical companies, medical device firms, and academic research, pushing demand for specialized services and software to manage complex biological data

Since Christmas eve nothing but green boxes

What motivates peope to post over Christmas on a share they dont own on what should be familiy time

Very very peculiar

And seems on LSE there are 3 or 4 on most discussio group s

13p

Nearly 200% up from 5p :)

404x

Good morning , back a few months ago I also picked up on this valuation gap

You put it far more succinctly

Great end to the year

Amd glad that the poachers have turned game keepers

Was a horrible board to be on prior to December

LT

Shows how grossly undervalued much.of AIM is!!

Myself and bmeister in one vakues less than one year revenues and no debt !

Crazy

Excellent news bmeister

Legend

Its all in the previous RNS

And of course its all relative to time frame

TTC

Now showing buys as blue , won't take much to get back past 0 .3

By CAGR , so many like myself and Trench are happy that Jesse is being incentivised by today's premium options

Bio Statistics  24% CAGR $40bln market

Regulatory authorities across the world require robust biometrics practices to approve new drugs. Biometrics typically incorporates three main areas:

1. Biostatistics: Supporting the design of clinical studies and analysis of resulting data

2. Statistical Programming: Use of programming language to process, analyse and visualise clinical data

3. Data Management: Setup and oversight of the collection, entry, and validation of clinical trial data

Lutra

Good afternoon,like a lot of AIM stocks its been a volatile 2025 but mgmt have delivered record revenues and are a whisker away from cash generation in 2026

Peers all trade at x 10 their annual revenues, PYC absolutely should be afforded the same valuation

Best wishes

Pity those saying 8p a few hours ago

Will show as a sell at 0 2775

Think PANR will finish 11p+

Moving up

The Company's actions to conserve cash whilst discussions continue, together with the drawdown from the CLF, has further extended the Company's cash runway and it is now forecast to last, with the continued support of creditors, until the end of February 2026, in line with the extension of the convertible loan. The Company will update shareholders as appropriate.

Thanks Doppo

Shrewed

Dizygit has been in INDI for a while so may explain things s ?

Well done Hydro

I'm thankfully now over 110% up from my 5p buys

Glad to see you're in profit